Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

Conclusion. Grade 2 or higher pneumonitis after durvalumab was not a prognostic factor of PFS in LA-NSCLC patients received durvalumab.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research